SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-21-132657
Filing Date
2021-04-27
Accepted
2021-04-27 07:30:53
Documents
9
Period of Report
2021-06-23

Document Format Files

Seq Description Document Type Size
1 DEF 14A d24332ddef14a.htm DEF 14A 422312
2 GRAPHIC g243322a.jpg GRAPHIC 3957
3 GRAPHIC g243322b.jpg GRAPHIC 1125
4 GRAPHIC g243322c.jpg GRAPHIC 921
5 GRAPHIC g243322d.jpg GRAPHIC 1356
6 GRAPHIC g243322e.jpg GRAPHIC 1205
7 GRAPHIC g243322f.jpg GRAPHIC 1079
8 GRAPHIC g24332g10n62.jpg GRAPHIC 46237
9 GRAPHIC g24332g14a35.jpg GRAPHIC 28499
  Complete submission text file 0001193125-21-132657.txt   540757
Mailing Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210
Business Address 321 SUMMER STREET SUITE 400 BOSTON MA 02210 857-330-4340
Inozyme Pharma, Inc. (Filer) CIK: 0001693011 (see all company filings)

IRS No.: 475129768 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39397 | Film No.: 21855877
SIC: 2834 Pharmaceutical Preparations